The new findings, says Korn, will encourage the researchers to clarify the status of 53 and p14ARF in
the individual tumors targeted.
Not exact matches
Merck took a precision approach and
targeted its medication towards patients whose
tumors express the PD - L1 protein, enrolling these
individuals in clinical trials.
Unlike conventional chemotherapies and radiation that indiscriminately eradicate fast - growing tissues and ravage people's bodies with side effects, new therapies specifically
target tumors using tailored cells from
individual patients.
Another possible application for the new machine is generating peptides that could be used as personalized cancer vaccines
targeting unique proteins found in
individual patients»
tumors.
Little is known, however, about the metabolic pathways that drive the growth of
individual glioblastoma subtypes — knowledge that is crucial for developing novel and effective
targeted therapies that might improve treatment for these lethal
tumors.
The study identified a multitude of events that could be selectively
targeted in the context of
individual pancreatic
tumors.
By shedding light on subtle distinctions in
tumor biology, these findings offer clues to designing more effective anticancer treatments to precisely
target tumors in
individual patients.
Whereas earlier, unsuccessful cancer vaccines usually
targeted a single distinctive cancer protein shared among patients, these new ones contain multiple mutated proteins, or «neoantigens,» that are specific to an
individual patient's
tumor.
Additional studies in which we more precisely define the mechanisms of resistance and growth in an
individual's
tumor with genomic sequencing, and other means, will be important to maximize the ability to
target all the critical pathways to achieve greater success.»
In the next decade, molecular research is going to further develop along five lines: predictive medicine, that investigates the genetic conditions predisposing to
tumor risk; early molecular diagnosis; the evaluation of each patient's prognosis based on his / her genetic profile, in other words, the analysis of what kind of mutation affects the DNA of altered cells; the investigation of the
individual response to drugs, based on our genetic knowledge; «smart drugs», molecules able to hit the
target in a selective way, killing only the deprogrammed cells.»
My studies of cancer genomes have led to characterization of multiple pediatric and adult
tumor types, to development of methods that identify and characterize changes in genomic heterogeneity, to defining acquired resistance mechanisms to
targeted therapies and to designing novel, personalized vaccines for
individual patients.
Physicians with the Personalized Medicine Program at The Tisch Cancer Institute have initiated a phase I proof - of - concept study, a fully personalized multipeptide therapeutic vaccine designed to
target tumor - derived neoantigens for
individual patients.
«We're using the whole
tumor cell, and that allows us to stimulate a response that's broad, that's against multiple
targets, and that's against
targets that are unique to that
individual patient,» Avigan said.
Understanding the genetic makeup of canine cancer
tumors, and comparing their genetic makeup to those of people with cancer, will allow researchers to discover additional
targeted drug therapies and the least toxic doses of those therapies that are most effective in curing the
individual, whether canine or human.